首页> 美国卫生研究院文献>Scientific Reports >Comparison of Alterations in miRNA Expression in Matched Tissue and Blood Samples during Spinal Cord Glioma Progression
【2h】

Comparison of Alterations in miRNA Expression in Matched Tissue and Blood Samples during Spinal Cord Glioma Progression

机译:脊髓胶质瘤进展过程中组织和血液样本中miRNA表达变化的比较

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Abnormal expression of microRNAs (miRNAs) contributes to glioma initiation. However, the expression of miRNAs in tumour tissue or blood of spinal cord glioma (SCG) patients, particularly in high-grade spinal gliomas (Grade IV) known as glioblastoma (GBM), remains largely unknown. In this study we aimed to determine differentially expressed miRNAs (DEmiRNAs) in the tissue and blood between spinal cord glioblastoma (SC-GBM) patients and low grade SCG (L-SCG) patients. Additionally, we predicted key miRNA targets and pathways that may be critical in glioma development using pathway and gene ontology analysis. A total of 74 miRNAs were determined to be differentially expressed (25 upregulated and 49 downregulated) in blood, while 207 miRNAs (20 up-regulated and 187 down-regulated) were identified in tissue samples. Gene ontology analysis revealed multicellular organism development and positive regulation of macromolecule metabolic process to be primarily involved. Pathway analysis revealed “Glioma”, “Signalling pathways regulating pluripotency of stem cells” to be the most relevant pathways. miRNA-mRNA analysis revealed that hsa-miRNA3196, hsa-miR-27a-3p, and hsa-miR-3664-3p and their target genes are involved in cancer progression. Our study provides a molecular basis for SCG pathological grading based on differential miRNA expression.
机译:microRNA(miRNA)的异常表达有助于神经胶质瘤的发生。然而,miRNA在脊髓神经胶质瘤(SCG)患者的肿瘤组织或血液中的表达,特别是在称为成胶质母细胞瘤(GBM)的高级脊髓神经胶质瘤(IV级)中的表达仍是未知的。在这项研究中,我们旨在确定脊髓胶质母细胞瘤(SC-GBM)患者和低度SCG(L-SCG)患者之间组织和血液中差异表达的miRNA(DEmiRNA)。此外,我们使用通路和基因本体分析,预测了可能对神经胶质瘤发展至关重要的关键miRNA靶标和通路。总共确定了74个miRNA在血液中差异表达(25个上调和49个下调),而在组织样本中鉴定出207个miRNA(20个上调和187个下调)。基因本体分析表明主要涉及多细胞生物的发展和大分子代谢过程的积极调控。途径分析显示“胶质瘤”,“调节干细胞多能性的信号传导途径”是最相关的途径。 miRNA-mRNA分析显示,hsa-miRNA3196,hsa-miR-27a-3p和hsa-miR-3664-3p及其靶基因与癌症进展有关。我们的研究为基于差异miRNA表达的SCG病理分级提供了分子基础。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号